Skip to main content
Premium Trial:

Request an Annual Quote

Ortho-Clinical Kills Alzheimer s License with SynX

NEW YORK, March 5 (GenomeWeb News) - Ortho-Clinical Diagnostics has ended an exclusive agreement to license certain Alzheimer's diagnostics technology from SynX Pharma, and has stopped trying to develop the technology, SynX said today.


As a result, Toronto-based SynX has re-acquired from Ortho the worldwide rights to the technology, the company said.


SynX won a USpatent for the technology in September 2002, and licensed it exclusively to Ortho one month later. SynX  said it plans to "pick up where Ortho has left off" and continue developing the Alzheimer's technology. The company will begin seeking non-exclusive licensing partners and consider plans to add it to its Nexus Dx point-of-care product line.

The Scan

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.

Family Genetic Risk Score Linked to Diagnostic Trajectory in Psychiatric Disorders

Researchers in JAMA Psychiatry find ties between high or low family genetic risk scores and diagnostic stability or change in four major psychiatric disorders over time.

Study Questions Existence of Fetal Microbiome

A study appearing in Nature this week suggests that the reported fetal microbiome might be the result of sample contamination.

Fruit Fly Study Explores Gut Microbiome Effects on Circadian Rhythm

With gut microbiome and gene expression experiments, researchers in PNAS see signs that the microbiome contributes to circadian rhythm synchronicity and stability in fruit flies.